MILANESI L.

Last name: MILANESI L.

2021 (v1)

Publication

Metadata-only

A boron delivery antibody (BDA) with boronated specific residues: New perspectives in boron neutron capture therapy from an in silico investigation

Rondina A. Fossa P. Orro A.

Boron Neutron Capture Therapy (BNCT) is a tumor cell-selective radiotherapy based on a nuclear reaction that occurs when the isotope boron-10 (10B) is radiated by low-energy thermal neutrons or epithermal neutrons, triggering a nuclear fission response and enabling a selective administration of irradiation to cells. Hence, we need to create...

Uploaded on: April 14, 2023
2021 (v1)

Publication

Metadata-only

BNCT: development of a novel Boron Delivery Antibody (BDA) by means of specific residues replacement

Rondina A. Orro A. Milanesi L.

No description

Uploaded on: April 14, 2023
2013 (v1)

Publication

Metadata-only

Homology modeling, docking studies and molecular dynamic simulations using GPU architecture to probe the type-11 Phosphodiesterase (PDE11) catalytic site: a computational approach for the rational design of selective inhibitors.

CICHERO, ELENA BRUNO, OLGA ROTOLO, CHIARA

No description

Uploaded on: April 14, 2023
2020 (v1)

Publication

Metadata-only

Rescuing defective CFTR applying a drug repositioning strategy based on computational studies, surface plasmon resonance and cell-based assays

D'Ursi P. Orro A. Urbinati C.

Cystic Fibrosis (CF) is caused by mutations (mainly F508del) of the cystic fibrosis transmembrane conductance regulator (CFTR). Current CF therapies are aimed at symptoms alleviation, calling for new drugs to rescue CFTR function. Hypothesis and objectives Drug repositioning is aimed at finding new applications for already marketed drugs,...

Uploaded on: April 14, 2023
2019 (v1)

Publication

Metadata-only

RESCUING DEFECTIVE CFTR APPLYING A DRUG REPOSITIONING STRATEGY

UGGERI, MATTEO Orro A. Urbinati C.

No description

Uploaded on: April 14, 2023
2019 (v1)

Publication

Metadata-only

Exploitation of a novel biosensor based on the full-length human F508del-CFTR with computational study, biochemical and biological assays for the characterization of a new Lumacaftor/Tezacaftor analogue.

D'Ursi P. Uggeri M. Urbinati C.

No description

Uploaded on: April 14, 2023

MILANESI L.

Recent uploads